Physician

Savitha Balaraman, MD

According to 2025 Medicare claims, Savitha Balaraman, MD (NPI: 1083696694) practices medical oncology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Oakland, MI. This provider's primary affiliated billing organization is MICHIGAN HEALTHCARE PROFESSIONALS PC (NPI: 1295023547; TIN: 451674932) and primary practice location at 48073-9998. Balaraman is affiliated with the Honest ACO of Michigan LLC (ACO ID: D0236), participating under the REACH model.

Balaraman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 691 traditional Medicare patients, billed 220,170 HCPCS/CPT codes, and received $3,185,026 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,445 prescription claims across 513 beneficiaries totaling $6,185,250 in drug costs, led by Xtandi (Enzalutamide). 2022 DME data shows 46 claims. Open Payments data shows 21 records totaling $68,267. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,745,980 to $6,185,250. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $2,672 to $149.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	771	181,169	$2,663,958
2016	727	122,888	$2,206,150
2017	731	128,542	$2,422,652
2018	723	197,825	$2,806,462
2019	718	169,746	$3,064,364
2020	618	123,188	$2,320,489
2021	587	117,110	$1,822,451
2022	591	132,244	$2,438,751
2023	635	178,820	$2,574,004
2024	691	220,170	$3,185,026

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	383	2,276	$1,745,980
2016	409	2,410	$2,217,914
2017	416	2,594	$3,300,233
2018	453	2,833	$3,490,410
2019	444	2,469	$3,216,672
2020	423	2,186	$4,351,821
2021	403	2,116	$4,397,615
2022	418	1,945	$3,436,693
2023	439	2,021	$4,723,374
2024	513	2,445	$6,185,250

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	77	$36,400
2016	N/R	106	$14,784
2017	N/R	66	$19,723
2018	N/R	27	$3,697
2019	N/R	34	$1,624
2020	N/R	N/R	N/R
2021	N/R	11	$211
2022	N/R	46	$2,815
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	319	811	$70
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	157	327	$63
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	150	206	$40
80047	Blood test, basic group of blood chemicals (calcium, ionized)	409	1,599	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	418	1,830	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	140	4,365	$1,981,954
Ibrance	Palbociclib	35	980	$537,247
Lenalidomide	Lenalidomide	26	714	$405,219
Kisqali	Ribociclib Succinate	26	738	$362,787
Verzenio	Abemaciclib	21	588	$300,960

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$90	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	20	$68,177	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Savitha Balaraman, MD?

Tedicare shows public-source Medicare data for Savitha Balaraman, MD (NPI 1083696694), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Savitha Balaraman, MD have ACO affiliation data?

Savitha Balaraman, MD is shown with ACO affiliation data for Honest ACO of Michigan LLC (REACH, ACO ID D0236).

What billing organization is linked to Savitha Balaraman, MD?

Savitha Balaraman, MD is linked to MICHIGAN HEALTHCARE PROFESSIONALS PC (billing NPI 1295023547) in the available physician profile data.

Does Savitha Balaraman, MD have Open Payments data?

Savitha Balaraman, MD has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.